Selected article for: "SARS CoV specific antibody detection and specific antibody detection"
Author: de Vries, A. A. F.
Title: SARS-CoV-2/COVID-19: a primer for cardiologists
  • Cord-id: 8rmqg4rf
  • Document date: 2020_7_15
    • ID: 8rmqg4rf
    Snippet: In the late autumn of 2019, a new potentially lethal human coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China. The pandemic spread of this zoonotic virus has created a global health emergency and an unprecedented socioeconomic crisis. The severity of coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV‑2, is highly variable. Most patients (~85%) develop no or mild symptoms, while others become seriously ill, some succumbin
    Document: In the late autumn of 2019, a new potentially lethal human coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China. The pandemic spread of this zoonotic virus has created a global health emergency and an unprecedented socioeconomic crisis. The severity of coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV‑2, is highly variable. Most patients (~85%) develop no or mild symptoms, while others become seriously ill, some succumbing to disease-related complications. In this review, the SARS-CoV‑2 life cycle, its transmission and the clinical and immunological features of COVID-19 are described. In addition, an overview is presented of the virological assays for detecting ongoing SARS-CoV‑2 infections and the serological tests for SARS-CoV-2-specific antibody detection. Also discussed are the different approaches to developing a COVID-19 vaccine and the perspectives of treating COVID-19 with antiviral drugs, immunomodulatory agents and anticoagulants/antithrombotics. Finally, the cardiovascular manifestations of COVID-19 are briefly touched upon. While there is still much to learn about SARS-CoV‑2, the tremendous recent advances in biomedical technology and knowledge and the huge amount of research into COVID-19 raise the hope that a remedy for this disease will soon be found. COVID-19 will nonetheless have a lasting impact on human society. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12471-020-01475-1) contains supplementary material, which is available to authorized users.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • abdominal pain and acute coronary syndrome: 1
    • abdominal pain and acute heart failure: 1, 2
    • abdominal pain and acute myocardial injury: 1
    • abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abdominal pain and acute phase protein: 1
    • abdominal pain and acute respiratory failure: 1, 2, 3, 4, 5, 6
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • abdominal pain and admission mechanical ventilation: 1, 2
    • abdominal pain and low respiratory: 1, 2, 3, 4, 5, 6
    • abdominal pain and low respiratory tract: 1
    • abdominal pain and lung disease: 1, 2, 3, 4, 5, 6, 7
    • abdominal pain and lung injury: 1, 2, 3, 4, 5
    • abdominal pain and lung pathology: 1
    • abdominal pain and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7
    • abdominal pain and lymphocyte neutrophil ratio: 1, 2, 3, 4, 5
    • accessory protein and activator transducer: 1, 2, 3
    • accessory protein and acute ards respiratory distress syndrome: 1
    • accessory protein and acute lung injury: 1